Skip to main content
SpringerLink
Log in

The Heart in Fabry Disease – from Pathogenesis to Enzyme Replacement Therapy

  • Chapter
  • First Online:
Fabry Disease

  • 1184 Accesses

Abstract

The cardiovascular involvement in Fabry disease is progressive, and accounts for one of the major reasons for abbreviated life expectancy and increased morbidity. The majority of patients develop signs and symptoms, related to heart failure and arrhythmias. Hypertrophic cardiomyopathy, in later stages combined with myocardial fibrosis, is one of the leading features. Both genders are affected, and females develop severe cardiac Fabry disease approximately 10–15 years later in life than male patients. Diastolic dysfunction and reduced longitudinal mid-wall related systolic function are the mechanical consequences of the myocardial and epithelial changes related to accumulation of the storage material in different cardiac components. The direct involvement of the conduction system and myocardial scar formation are the contributing factors for the development of complex arrhythmias, accompanied by disturbances in the autonomic control of the heart rate and its variability. Some of these changes are readily detectable in childhood and adolescence. Treatment of the cardiovascular involvement is crucial and consists of concomitant management of clinical symptoms and on enzyme replacement therapy. Different aspects of the cardiac disease and possible treatment options are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38(11):750–760

    Article  PubMed  CAS  Google Scholar 

  2. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34(3):236–242

    Article  PubMed  CAS  Google Scholar 

  3. Elleder M (2008) Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch 452(6):705, author reply 7–8

    Article  PubMed  Google Scholar 

  4. Elleder M, Bradova V, Smid F, Budesinsky M, Harzer K, Kustermann-Kuhn B et al (1990) Cardiocyte storage and hypertrophy as a sole manifestation of Fabry’s disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 417(5):449–455

    Article  PubMed  CAS  Google Scholar 

  5. Schiffmann R, Rapkiewicz A, Abu-Asab M, Ries M, Askari H, Tsokos M et al (2006) Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch 448(3):337–343

    Article  PubMed  Google Scholar 

  6. Kampmann C, Baehner F, Ries M, Beck M (2002) Cardiac involvement in Anderson-Fabry disease. J Am Soc Nephrol 13(Suppl 2):S147–S149

    PubMed  Google Scholar 

  7. Linhart A, Lubanda JC, Palecek T, Bultas J, Karetova D, Ledvinova J et al (2001) Cardiac manifestations in Fabry disease. J Inherit Metab Dis 24(Suppl 2):75–83, discussion 65

    Article  PubMed  Google Scholar 

  8. Uchino M, Uyama E, Kawano H, Hokamaki J, Kugiyama K, Murakami Y et al (1995) A histochemical and electron microscopic study of skeletal and cardiac muscle from a Fabry disease patient and carrier. Acta Neuropathol 90(3):334–338

    Article  PubMed  CAS  Google Scholar 

  9. Hilz MJ (2002) Evaluation of peripheral and autonomic nerve function in Fabry disease. Acta Paediatr Suppl 91(439):38–42

    Article  PubMed  CAS  Google Scholar 

  10. Hilz MJ, Brys M, Marthol H, Stemper B, Dutsch M (2004) Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology 62(7):1066–1072

    Article  PubMed  CAS  Google Scholar 

  11. Kampmann C, Linhart A, Baehner F, Palecek T, Wiethoff CM, Miebach E et al (2008) Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 130(3):367–373

    Article  PubMed  Google Scholar 

  12. Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A et al (2007) Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28(10):1228–1235

    Article  PubMed  Google Scholar 

  13. Kampmann C, Baehner F, Whybra C, Martin C, Wiethoff CM, Ries M et al (2002) Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 40(9):1668–1674

    Article  PubMed  Google Scholar 

  14. Whybra C, Kampmann C, Willers I, Davies J, Winchester B, Kriegsmann J et al (2001) Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 24(7):715–724

    Article  PubMed  CAS  Google Scholar 

  15. Kampmann C, Wiethoff CM, Whybra C, Baehner FA, Mengel E, Beck M (2008) Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr 97(4):463–469

    Article  PubMed  Google Scholar 

  16. Beck M, Whybra C, Wendrich K, Gal A, Ries M (2001) Anderson-Fabry disease in children and adolescents. Contrib Nephrol 136:251–255

    Article  PubMed  Google Scholar 

  17. Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G et al (2006) Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 95(1):86–92

    Article  PubMed  Google Scholar 

  18. Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP et al (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 64(5):550–555

    Article  PubMed  Google Scholar 

  19. Hulkova H, Ledvinova J, Poupetova H, Bultas J, Zeman J, Elleder M (1999) Postmortem diagnosis of Fabry disease in a female heterozygote leading to the detection of undiagnosed manifest disease in the family. Cas Lek Cesk 138(21):660–664

    PubMed  CAS  Google Scholar 

  20. Ashrafian H, Redwood C, Blair E, Watkins H (2003) Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion. Trends Genet 19(5):263–268

    Article  PubMed  CAS  Google Scholar 

  21. Lucke T, Hoppner W, Schmidt E, Illsinger S, Das AM (2004) Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts. Mol Genet Metab 82(1):93–97

    Article  PubMed  CAS  Google Scholar 

  22. Jung WI, Sieverding L, Breuer J, Hoess T, Widmaier S, Schmidt O et al (1998) 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 97(25):2536–2542

    Article  PubMed  CAS  Google Scholar 

  23. Chimenti C, Hamdani N, Boontje NM, DeCobelli F, Esposito A, Bronzwaer JG et al (2008) Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease. Am J Pathol 172(6):1482–1490

    Article  PubMed  CAS  Google Scholar 

  24. Barbey F, Brakch N, Linhart A, Rosenblatt-Velin N, Jeanrenaud X, Qanadli S et al (2006) Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol 26(4):839–844

    Article  PubMed  CAS  Google Scholar 

  25. Funabashi N, Toyozaki T, Matsumoto Y, Yonezawa M, Yanagawa N, Yoshida K et al (2003) Images in cardiovascular medicine. Myocardial fibrosis in fabry disease demonstrated by multislice computed tomography: comparison with biopsy findings. Circulation 107(19):2519–2520

    Article  PubMed  Google Scholar 

  26. Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudova J, Karetova D et al (2000) New insights in cardiac structural changes in patients with Fabry’s disease. Am Heart J 139(6):1101–1108

    Article  PubMed  CAS  Google Scholar 

  27. Olivotto I, Cecchi F, Camici PG (2004) Coronary microvascular dysfunction and ischemia in hypertrophic cardiomyopathy. Mechanisms and clinical consequences. Ital Heart J 5(8):572–580

    PubMed  Google Scholar 

  28. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG (2003) Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 349(11):1027–1035

    Article  PubMed  CAS  Google Scholar 

  29. MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38(11):769–775

    Article  PubMed  CAS  Google Scholar 

  30. MacDermot KD, Holmes A, Miners AH (2001) Natural history of Fabry disease in affected males and obligate carrier females. J Inherit Metab Dis 24(Suppl 2):13–14, discussion 1–2

    Article  PubMed  Google Scholar 

  31. Kampmann C, Wiethoff CM, Martin C, Wenzel A, Kampmann R, Whybra C et al (2002) Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy. Acta Paediatr Suppl 91(439):21–27

    Article  PubMed  CAS  Google Scholar 

  32. von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG et al (1991) An atypical variant of Fabry’s disease with manifestations confined to the myocardium. N Engl J Med 324(6):395–399

    Article  Google Scholar 

  33. Cantor WJ, Butany J, Iwanochko M, Liu P (1998) Restrictive cardiomyopathy secondary to Fabry’s disease. Circulation 98(14):1457–1459

    Article  PubMed  CAS  Google Scholar 

  34. Morrone A, Cavicchi C, Bardelli T, Antuzzi D, Parini R, Di Rocco M et al (2003) Fabry disease: molecular studies in Italian patients and X inactivation analysis in manifesting carriers. J Med Genet 40(8):e103

    Article  PubMed  CAS  Google Scholar 

  35. Dobrovolny R, Dvorakova L, Ledvinova J, Magage S, Bultas J, Lubanda JC et al (2005) Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med 83(8):647–654

    Article  PubMed  CAS  Google Scholar 

  36. Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA et al (2004) Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 110(9):1047–1053

    Article  PubMed  CAS  Google Scholar 

  37. Magage S, Linhart A, Bultas J, Vojacek J, Mates M, Palecek T et al (2005) Fabry disease: percutaneous transluminal septal myocardial ablation markedly improved symptomatic left ventricular hypertrophy and outflow tract obstruction in a classically affected male. Echocardiography 22(4):333–339

    Article  PubMed  Google Scholar 

  38. Burda CD, Winder PR (1967) Angiokeratoma corporis diffusum universale (Fabry’s disease) in female subjects. Am J Med 42(2):293–301

    Article  PubMed  CAS  Google Scholar 

  39. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ et al (2003) Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24(23):2151–2155

    Article  PubMed  Google Scholar 

  40. Weidemann F, Breunig F, Beer M, Sandstede J, Stork S, Voelker W et al (2005) The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26(12):1221–1227

    Article  PubMed  Google Scholar 

  41. Kampmann C, Baehner FA, Whybra C, Bajbouj M, Baron K, Knuf M et al (2005) The right ventricle in Fabry disease. Acta Paediatr Suppl 94(447):15–18, discussion 9–10

    Article  PubMed  CAS  Google Scholar 

  42. Goldman ME, Cantor R, Schwartz MF, Baker M, Desnick RJ (1986) Echocardiographic abnormalities and disease severity in Fabry’s disease. J Am Coll Cardiol 7(5):1157–1161

    Article  PubMed  CAS  Google Scholar 

  43. Pieroni M, Chimenti C, Russo A, Russo MA, Maseri A, Frustaci A (2004) Tissue Doppler imaging in Fabry disease. Curr Opin Cardiol 19(5):452–457

    Article  PubMed  Google Scholar 

  44. Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A (2003) Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 107(15):1978–1984

    Article  PubMed  Google Scholar 

  45. Hasegawa H, Takano H, Shindo S, Takeda S, Funabashi N, Nakagawa K et al (2006) Images in cardiovascular medicine. Transition from left ventricular hypertrophy to massive fibrosis in the cardiac variant of Fabry disease. Circulation 113(16):e

    Article  Google Scholar 

  46. Cantor WJ, Daly P, Iwanochko M, Clarke JT, Cusimano RJ, Butany J (1998) Cardiac transplantation for Fabry’s disease. Can J Cardiol 14(1):81–84

    PubMed  CAS  Google Scholar 

  47. Becker AE, Schoorl R, Balk AG, van der Heide RM (1975) Cardiac manifestations of Fabry’s disease. Report of a case with mitral insufficiency and electrocardiographic evidence of myocardial infarction. Am J Cardiol 36(6):829–835

    Article  PubMed  CAS  Google Scholar 

  48. Kaneski CR, Moore DF, Ries M, Zirzow GC, Schiffmann R (2006) Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease. Neurology 67(11):2045–2047

    Article  PubMed  CAS  Google Scholar 

  49. DeGraba T, Azhar S, Dignat-George F, Brown E, Boutiere B, Altarescu G et al (2000) Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 47(2):229–233

    Article  PubMed  CAS  Google Scholar 

  50. Kalliokoski RJ, Kalliokoski KK, Sundell J, Engblom E, Penttinen M, Kantola I et al (2005) Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease. J Inherit Metab Dis 28(4):563–573

    Article  PubMed  CAS  Google Scholar 

  51. Elliott PM, Kindler H, Shah JS, Sachdev B, Rimoldi OE, Thaman R et al (2006) Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 92(3):357–360

    Article  PubMed  CAS  Google Scholar 

  52. Chimenti C, Morgante E, Tanzilli G, Mangieri E, Critelli G, Gaudio C et al (2008) Angina in fabry disease reflects coronary small vessel disease. Circ Heart Fail 1(3):161–169

    Article  PubMed  Google Scholar 

  53. Dimitrow PP, Krzanowski M, Undas A (2005) Reduced coronary flow reserve in Anderson-Fabry disease measured by transthoracic Doppler echocardiography. Cardiovasc Ultrasound 3:11

    Article  PubMed  Google Scholar 

  54. Ogawa T, Kawai M, Matsui T, Seo A, Aizawa O, Hongo K et al (1996) Vasospastic angina in a patient with Fabry’s disease who showed normal coronary angiographic findings. Jpn Circ J 60(5):315–318

    Article  PubMed  CAS  Google Scholar 

  55. Eckart RE, Kinney KG, Belnap CM, Le TD (2000) Ventricular fibrillation refractory to automatic internal cardiac defibrillator in Fabry’s disease. Review of cardiovascular manifestations. Cardiology 94(3):208–212

    Article  PubMed  CAS  Google Scholar 

  56. Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P et al (2005) Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 96(6):842–846

    Article  PubMed  Google Scholar 

  57. Igawa O, Miake J, Hisatome I (2005) Ventricular tachycardias and dilated cardiomyopathy caused by Fabry disease. Pacing Clin Electrophysiol 28(10):1142–1143

    Article  PubMed  Google Scholar 

  58. Pochis WT, Litzow JT, King BG, Kenny D (1994) Electrophysiologic findings in Fabry’s disease with a short PR interval. Am J Cardiol 74(2):203–204

    Article  PubMed  CAS  Google Scholar 

  59. Murata R, Takatsu H, Noda T, Nishigaki K, Tsuchiya K, Takemura G et al (1999) Fifteen-year follow-up of a heterozygous Fabry’s disease patient associated with pre-excitation syndrome. Intern Med 38(6):476–481

    Article  PubMed  CAS  Google Scholar 

  60. Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR et al (2005) Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 352(4):362–372

    Article  PubMed  CAS  Google Scholar 

  61. Ikari Y, Kuwako K, Yamaguchi T (1992) Fabry’s disease with complete atrioventricular block: histological evidence of involvement of the conduction system. Br Heart J 68(3):323–325

    Article  PubMed  CAS  Google Scholar 

  62. Matsui S, Murakami E, Takekoshi N, Hiramaru Y, Kin T (1977) Cardiac manifestations of Fabry’s disease. Report of a case with pulmonary regurgitation diagnosed on the basis of endomyocardial biopsy findings. Jpn Circ J 41(9):1023–1036

    Article  PubMed  CAS  Google Scholar 

  63. Desnick RJ, Blieden LC, Sharp HL, Hofschire PJ, Moller JH (1976) Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies. Circulation 54(5):818–825

    Article  PubMed  CAS  Google Scholar 

  64. Ogawa K, Sugamata K, Funamoto N, Abe T, Sato T, Nagashima K et al (1990) Restricted accumulation of globotriaosylceramide in the hearts of atypical cases of Fabry’s disease. Hum Pathol 21(10):1067–1073

    Article  PubMed  CAS  Google Scholar 

  65. Ishii S, Kase R, Sakuraba H, Suzuki Y (1993) Characterization of a mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease. Biochem Biophys Res Commun 197(3):1585–1589

    Article  PubMed  CAS  Google Scholar 

  66. Ishii S, Chang HH, Kawasaki K, Yasuda K, Wu HL, Garman SC et al (2007) Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. Biochem J 406(2):285–295

    Article  PubMed  CAS  Google Scholar 

  67. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M et al (1995) An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med 333(5):288–293

    Article  PubMed  CAS  Google Scholar 

  68. Ommen SR, Nishimura RA, Edwards WD (2003) Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy? Heart 89(8):929–930

    Article  PubMed  CAS  Google Scholar 

  69. Monserrat L, Gimeno-Blanes JR, Marin F, Hermida-Prieto M, Garcia-Honrubia A, Perez I et al (2007) Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 50(25):2399–2403

    Article  PubMed  Google Scholar 

  70. Sachdev B, Elliott PM (2002) Isolated cardiac manifestations in Fabry disease: the UK experience. Acta Paediatr Suppl 91(439):28–30

    Article  PubMed  CAS  Google Scholar 

  71. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ et al (2002) Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105(12):1407–1411

    Article  PubMed  CAS  Google Scholar 

  72. Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ et al (2005) Pediatric Fabry disease. Pediatrics 115(3):e344–e355

    Article  PubMed  Google Scholar 

  73. Frustaci A, Chimenti C, Ricci R, Natale L, Russo MA, Pieroni M et al (2001) Improvement in cardiac function in the cardiac variant of Fabry’s disease with galactose-infusion therapy. N Engl J Med 345(1):25–32

    Article  PubMed  CAS  Google Scholar 

  74. Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285(21):2743–2749

    Article  PubMed  CAS  Google Scholar 

  75. Kampmann C, Baehner F, Kim KS, Bajbouj M, Beck M (2002) Influence of Enzyme Replacement Therapy (ERT) on Anderson Fabry Disease associated Hypertrophic Infiltrative Cardiomyopathy (HIC). Eur J Pediatr 161(2):R5

    Google Scholar 

  76. Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J et al (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94(2):153–158

    Article  PubMed  CAS  Google Scholar 

  77. Beck M (2009) Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety. Expert Opin Biol Ther 9(2):255–261

    Article  PubMed  CAS  Google Scholar 

  78. Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C et al (2004) Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 34(12):838–844

    Article  PubMed  CAS  Google Scholar 

  79. Whybra C, Miebach E, Mengel E, Gal A, Baron K, Beck M et al (2009) A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med 11(6):441–449

    Article  PubMed  CAS  Google Scholar 

  80. Kampmann C, Linhart A, Devereux RB, Schiffmann R (2009) Effect of agalsidase alfa replacement therapy on fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis. Clin Ther 31(9):1966–1976

    Article  PubMed  CAS  Google Scholar 

  81. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21(2):345–354

    Article  PubMed  CAS  Google Scholar 

  82. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W et al (2003) Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 108(11):1299–1301

    Article  PubMed  CAS  Google Scholar 

  83. Spinelli L, Pisani A, Sabbatini M, Petretta M, Andreucci MV, Procaccini D et al (2004) Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry’s disease. Clin Genet 66(2):158–165

    Article  PubMed  CAS  Google Scholar 

  84. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S et al (2009) Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119(4):524–529

    Article  PubMed  CAS  Google Scholar 

  85. Pisani A, Spinelli L, Sabbatini M, Andreucci MV, Procaccini D, Abbaterusso C et al (2005) Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. Am J Kidney Dis 46(1):120–127

    Article  PubMed  CAS  Google Scholar 

  86. Kalliokoski RJ, Kantola I, Kalliokoski KK, Engblom E, Sundell J, Hannukainen JC et al (2006) The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. J Inherit Metab Dis 29(1):112–118

    Article  PubMed  CAS  Google Scholar 

  87. Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C (2006) Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69(7):1216–1221

    Article  PubMed  CAS  Google Scholar 

  88. Beer M, Weidemann F, Breunig F, Knoll A, Koeppe S, Machann W et al (2006) Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry’s cardiomyopathy. Am J Cardiol 97(10):1515–1518

    Article  PubMed  CAS  Google Scholar 

  89. Vedder AC, Breunig F, Donker-Koopman WE, Mills K, Young E, Winchester B et al (2008) Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 94(3):319–325

    Article  PubMed  CAS  Google Scholar 

  90. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry’s disease. N Engl J Med 345(1):9–16

    Article  PubMed  CAS  Google Scholar 

  91. Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M et al (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS – Fabry Outcome Survey. J Med Genet 46(8):548–552

    Article  PubMed  CAS  Google Scholar 

  92. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146(2):77–86

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Medicine, Johannes Gutenberg University Mainz, Mainz, Germany

    Christoph Kampmann

  2. Department of Internal Medicine, Carl’s University, Prague, Czech Republic

    Aleš Linhart

Authors
  1. Christoph Kampmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aleš Linhart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christoph Kampmann .

Editor information

Editors and Affiliations

  1. , Shaare Zedek Medical Center, Gaucher Clinic, Bayit Street 12, Jerusalem, 91034, Israel

    Deborah Elstein

  2. , Shaare Zedek Medical Center, Genetics Unit, Bayit Street 12, Jerusalem, 91031, Israel

    Gheona Altarescu

  3. University of Mainz, Children's Hospital, Langenbeckstrasse 1, Mainz, 55131, Germany

    Michael Beck

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Netherlands

About this chapter

Cite this chapter

Kampmann, C., Linhart, A. (2010). The Heart in Fabry Disease – from Pathogenesis to Enzyme Replacement Therapy. In: Elstein, D., Altarescu, G., Beck, M. (eds) Fabry Disease. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9033-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-90-481-9033-1_11

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-9032-4

  • Online ISBN: 978-90-481-9033-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation